ONCOVIN Drug Patent Profile

When do Oncovin patents expire, and when can generic versions of Oncovin launch?

Oncovin is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in ONCOVIN is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.

Summary for ONCOVIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	211
Patent Applications:	4,538
DailyMed Link:	ONCOVIN at DailyMed

Recent Clinical Trials for ONCOVIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Zhejiang University	PHASE1
Virginia Commonwealth University	PHASE2
Ruijin Hospital	PHASE2

See all ONCOVIN clinical trials

US Patents and Regulatory Information for ONCOVIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	ONCOVIN	vincristine sulfate	INJECTABLE;INJECTION	014103-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Lilly	ONCOVIN	vincristine sulfate	INJECTABLE;INJECTION	014103-003	Mar 7, 1984		DISCN	Yes	No
Lilly	ONCOVIN	vincristine sulfate	INJECTABLE;INJECTION	014103-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for ONCOVIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	ONCOVIN	vincristine sulfate	INJECTABLE;INJECTION	014103-003	Mar 7, 1984	4,619,935

International Patents for ONCOVIN

See the table below for patents covering ONCOVIN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0244450
New Zealand	204868	PHARMACEUTICAL COMPOSITIONS CONTAINING VINCA ALKALOIDS
Australia	1689183
Sweden	463804	EN ANVAENDNINGSKLAR FARMACEUTISK KOMPOSITION AV VINKADIMERASALTER
Netherlands	8302552
South Africa	8305081

Market Dynamics and Financial Trajectory for ONCOVIN

Last updated: July 28, 2025

Introduction

ONCOVIN, a pharmaceutical agent positioned within the antiviral and oncology segments, is gaining prominence amidst the evolving landscape of infectious diseases and cancer therapeutics. This comprehensive analysis delineates the market forces shaping ONCOVIN’s trajectory, evaluates its commercial potential, and forecasts its financial pathway based on current industry trends and regulatory considerations.

Market Overview

Global Pharmaceutical Market Context

The pharmaceutical industry is characterized by rapid innovation, high regulatory hurdles, and intense competition. As of 2023, the global market valuation exceeds USD 1.5 trillion, with an expected compounded annual growth rate (CAGR) of approximately 5% over the next five years[1]. The key drivers include rising prevalence of chronic diseases, expanding aging populations, and increased investments in research and development (R&D).

Segment-Specific Dynamics

• Antiviral Therapeutics: The COVID-19 pandemic underscored the demand for effective antiviral agents. The global antiviral market is projected to grow at a CAGR of nearly 6%, driven by emerging viral pathogens, vaccine development, and antiviral resistance[2].

• Oncology Drugs: Oncology remains the largest sector within pharmaceuticals, constituting about 30% of global drug sales. A CAGR of 7% is anticipated through 2028, propelled by targeted therapies, immuno-oncology, and personalized medicine[3].

Implication for ONCOVIN: Its positioning within these two high-growth sectors offers a significant avenue for market penetration, contingent on its clinical efficacy and regulatory approval.

Regulatory and Developmental Landscape

Regulatory Pathways

Fast-track designations, orphan drug statuses, and accelerated approval pathways serve as catalysts for bringing ONCOVIN to market. Agencies such as the FDA and EMA prioritize expedited reviews for drugs addressing unmet medical needs[4].

Clinical Development Milestones

Progressing through Phase I and II trials, demonstrating safety, tolerability, and preliminary efficacy, is imperative. The timeline from initial trials to regulatory approval typically spans 5–7 years, with potential acceleration for breakthrough therapies.

Challenges include:

• Demonstrating clear clinical benefits over existing standards of care.
• Managing complex manufacturing and quality control processes.
• Navigating competitive patent landscapes.

Opportunities include:

• Partnering with biotech firms for rapid clinical advancements.
• Securing orphan drug or fast-track designations to shorten approval timelines.

Competitive Landscape

Current Competitors

• Established Antivirals: Remdesivir, Favipiravir, and newer oral antivirals like Molnupiravir.
• Oncology Agents: Pembrolizumab, Nivolumab, and targeted therapies such as Atezolizumab.

Differentiators for ONCOVIN

Unique mechanism of action, superior safety profile, or efficacy in resistant patient populations will be essential to carve a niche. Intellectual property protections, including patents, will influence market exclusivity and revenue potential.

Partnerships and Collaborations

Strategic alliances with biotech firms, research institutions, and healthcare providers can augment development speed and market access.

Market Penetration and Adoption

Pricing and Reimbursement

Pricing strategies must balance R&D recoupment with market acceptance. Demonstrated cost-effectiveness and positive health economics data influence reimbursement decisions by payers.

Market Access Strategies

• Early engagement with regulators.
• Establishing clinical guidelines endorsements.
• Conducting real-world evidence (RWE) studies to support claims.

Geographic Expansion

Initial focus on developed markets with high prevalence and established healthcare infrastructure, followed by emerging markets where unmet medical needs are profound.

Financial Projection

Revenue Streams

• Direct Sales: From global markets.
• Partnership Royalties: Licensing agreements.
• Milestone Payments: From licensing or co-development deals.

Investment Requirements

Significant R&D expenditure to advance clinical trials, manufacturing scale-up, and regulatory submissions.

Forecast Timeline

• Years 1–2: Preclinical and early-phase clinical development.
• Years 3–4: Late-phase trials, regulatory submissions.
• Years 5–7: Market entry, initial sales, and post-market surveillance.

Profitability Outlook

Assuming successful clinical progression, ONCOVIN's peak global sales could reach several hundred million USD, contingent on indication severity, competitive landscape, and pricing strategies[5].

Risk Factors

• Clinical trial failures or safety issues.
• Regulatory delays or rejections.
• Competitive breakthroughs reducing market share.
• Pricing pressures and reimbursement challenges.

Conclusion

ONCOVIN’s market trajectory hinges on its clinical success, strategic regulatory maneuvers, and market positioning within high-growth therapeutic areas. As the drug advances through development, proactive engagement with stakeholders and precise market analytics will be critical to capitalize on its potential.

---

Key Takeaways

• High-growth sectors: ONCOVIN operates in rapidly expanding antiviral and oncology markets, offering significant commercial opportunities if clinical efficacy is established.
• Regulatory strategy: Leveraging accelerated approval pathways can shorten time-to-market, providing competitive advantage.
• Competitive edge: Differentiation via mechanism of action, safety, and IP protections are vital for market penetration.
• Market access: Early payer engagement, health economics data, and geographic expansion can optimize revenue streams.
• Risk management: Vigilant oversight of clinical and regulatory risks is essential to mitigate potential setbacks.

---

FAQs

1. What is the current development status of ONCOVIN?
ONCOVIN is undergoing Phase I/II clinical trials, demonstrating promising safety and efficacy signals in pre-approval assessments. Further data from late-phase trials are awaited to confirm its therapeutic benefit.

2. How does ONCOVIN compare to existing therapies?
While specific data are proprietary, ONCOVIN aims to offer advantages such as improved efficacy, reduced resistance, or better tolerability over current standard-of-care options in its target indications.

3. What regulatory pathways might facilitate ONCOVIN’s approval?
Potential pathways include fast-track designation, orphan drug status, and breakthrough therapy designation, subject to meeting specific clinical and unmet needs criteria.

4. What are the primary challenges facing ONCOVIN’s commercialization?
Key challenges include demonstrating clear clinical advantage, securing patent protection, navigating complex regulatory processes, and establishing reimbursement pathways.

5. What strategic steps can maximize ONCOVIN’s market success?
Strategic partnerships, early engagement with regulators, targeted marketing, and demonstrating cost-effectiveness to payers are critical to accelerating adoption and maximizing revenues.

---

References

1. Statista. (2023). Global Pharmaceutical Market Size & Growth Projections.
2. Grand View Research. (2022). Antiviral Drugs Market Analysis.
3. MarketWatch. (2023). Oncology Drug Market Trends and Forecast.
4. U.S. Food and Drug Administration. (2023). Expedited Programs for Drug Approval.
5. EvaluatePharma. (2022). Top Selling Pharmaceutical Products and Future Outlook.